H.C Wainwright Initiates X T L Biopharmaceuticals With Buy

Analysts at H.C Wainwright initiated coverage on

with a Buy rating. The target price for XTL Biopharmaceuticals is set to $6. XTL Biopharmaceuticals shares have dropped 30.58 percent over the past 52 weeks, while the S&P 500 index has surged 11.15 percent in the same period. XTL Biopharmaceuticals' shares rose 14.14 percent to $2.30 in pre-market trading.